The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design (2009)
Hooven, F.H., Adachi, J.D., Adami, S., Boonen, S., Compston, J., Cooper, C., ...
Summary: the Global Longitudinal study of Osteoporosis in Women (GLOW) is a prospective cohort study involving 723 physicians and 60,393 women subjects ≥55 years. The data will provide insights...
Cranney, A., Wells, G.A., Yetisir, L., Adami, S., Cooper, C., Delmas, P.D., ...
Summary: this analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density....
Cranney, A, Wells, G A, Yetisir, E, Adami, S, Cooper, C, Delmas, P D, ...
SUMMARY: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density....
Bruyère, Olivier, Varela, AR, Adami, S, Detilleux, Johann, Rabenda, Véronique, Hiligsmann, Mickaël, ...
The objective of the study assess the relationship between bone mineral density (BMD) loss over time and fracture incidence in postmenopausal women. This is a posthoc analysis that includes women...
Effects of Strontium Ranelate on Spinal Osteoarthritis Progression (2008)
Bruyère, Olivier, Delferriere, D, Roux, C, Wark, J D, Spector, T, Devogelaer, J P, ...
OBJECTIVE: The aim of this study was to determine whether a 3-year treatment with strontium ranelate could delay the progression of spinal osteoarthritis (OA). METHODS: This study was a post-hoc...
GEUSENS, Piet, Roux, CH, Reid, DM, Lems, WF, Adami, S, Adachi, JD, ...
Many randomized controlled trials (RCTs) have investigated drug treatment for women at high risk of fracture, with a reduction in fracture risk as their end point. There has also been progress in...
Cooper, C., Jakob, F., Chinn, C., Martin-Mola, E., Fardellone, P., Adami, S., ...
SUMMARY: In this observational study of women with an inadequate clinical outcome to osteoporosis therapy, those with a fracture at baseline were more likely to sustain an incident fracture and have...
Delmas, PD, Adami, S, Strugala, C, Stakkestad, JA, Reginster, Jean-Yves, Felsenberg, D, ...
Objective. Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously...
Reginster, Jean-Yves, Adami, S, Lakatos, P, Greenwald, M, Stepan, JJ, Silverman, SL, ...
BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has...
Reginster, Jean-Yves, Felsenberg, D, Cooper, C, Stakkestad, JA, Miller, PD, Kendler, DL, ...
Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect...
Reginster, J.Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J.J., Silverman, S.L., ...
BACKGROUND: Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has...
Jakob, F., Marin, F., Martin-Mola, E., Torgerson, D., Fardellone, P., Adami, S., ...
BACKGROUND: Osteoporotic fractures remain a major public health problem. Currently available osteoporosis therapies significantly reduce the risk of fractures, but up to 50% of patients have an...
Jakob, F., Marín, F., Martín-Mola, E., Torgerson, D., Fardellone, P., Adami, S., ...
Background: Osteoporotic fractures remain a major public health problem. Currently available osteoporosis therapies significantly reduce the risk of fractures, but up to 50% of patients have an...
Jakob, F., Marín, F., Martín-Mola, E., Torgerson, D., Fardellone, P., Adami, S., ...
Background: Osteoporotic fractures remain a major public health problem. Currently available osteoporosis therapies significantly reduce the risk of fractures, but up to 50% of patients have an...
Jakob, F., Marín, F., Martín-Mola, E., Torgerson, D., Fardellone, P., Adami, S., ...
Background: Osteoporotic fractures remain a major public health problem. Currently available osteoporosis therapies significantly reduce the risk of fractures, but up to 50% of patients have an...
Reginster, Jean-Yves, Seeman, E, De Vernejoul, MC, Adami, S, Compston, J, Phenekos, C, ...
Background: Strontium ranelate, a new oral drug shown to reduce vertebral fracture risk in postmenopausal women with osteoporosis, was studied in the Treatment of Peripheral Osteoporosis (TROPOS)...
Tannenbaum, H, Berenbaum, F, Reginster, Jean-Yves, Zacher, J, Robinson, J, Poor, G, ...
Objectives: To compare the efficacy and safety of lumiracoxib with placebo and celecoxib for osteoarthritis (OA) in a 13 week, multicentre, randomised, double blind study. Methods: After a 327 day...
Meunier, PJ, Roux, C, Seeman, E, Ortolani, S, Badurski, JE, Spector, TD, ...
BACKGROUND: Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally active drug...
ORWOLL, E, SCHEELE, W, PAUL, S, ADAMI, S, SYVERSEN, U, DIEZ-PEREZ, A, ...
Effects of risedronate on risk of femoral neck and intertrochanteric fractures (2002)
Adami, S, Bensen, WG, Miller, PD, Meunier, P, GEUSENS, Piet
LUC, Inst Biomed Res, Diepenbeek, Belgium. Ctr Osped Clin Valeggio, Valeggio Sul Mincio, Italy. McMaster Univ, Hamilton, ON, Canada. Colorado Ctr Bone Res, Denver, CO USA. Hop Edouard Herriot, Lyon,...
Effects of risedronate on risk of femoral neck and intertrochanteric fractures (2002)
Adami, S, Bensen, WG, Miller, PD, Meunier, P, GEUSENS, Piet
LUC, Inst Biomed Res, Diepenbeek, Belgium. Ctr Osped Clin Valeggio, Valeggio Sul Mincio, Italy. McMaster Univ, Hamilton, ON, Canada. Colorado Ctr Bone Res, Denver, CO USA. Hop Edouard Herriot, Lyon,...
Effect of risedronate on the risk of hip fracture in elderly women (2001)
McClung, MR, Miller, PD, Zippel, H, Bensen, WG, Roux, C, Adami, S, ...
Background: Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. Methods: We studied 5445 women 70 to 79 years old who had osteoporosis...
Effect of risedronate on the risk of hip fracture in elderly women (2001)
McClung, MR, Miller, PD, Zippel, H, Bensen, WG, Roux, C, Adami, S, ...
Background: Risedronate increases bone mineral density in elderly women, but whether it prevents hip fracture is not known. Methods: We studied 5445 women 70 to 79 years old who had osteoporosis...
Effect of risedronate on the risk of hip fracture in elderly women. (2001)
MCCLUNG, MR, GEUSENS, P, MILLER, PD, ZIPPEL, H, BENSEN, WG, ROUX, C, ...
Background for studies on the treatment of male osteoporosis: state of the art. (2000)
Kaufman, Jean, JOHNELL, O, ABADIE, E, ADAMI, S, AUDRAN, M, AVOUAC, B, ...
Response of Renal Transplanted Patients to Oral Calcium Load (1990)
Graziani, G., Castelnovo, Claudia, Aroldi, Adriana, Adami, S., Viganò, Elena, Casati, S., ...
In a previous study we demonstrated that cyclosporin-treated renal transplanted patients have a reduced 1,25(OH)2D3 synthesis in comparison with azathioprine-treated transplanted patients. To assess...
Familial Benign Hypercalcaemia: STUDY OF A LARGE FAMILY (1983)
MENKO, F. H., BIJVOET, O. L. M., SANDLER, L. M., ADAMI, S., O'RIORDAN, J. L. H., ...
Twenty-seven hypercalcaemic subjects were identified in three generations of a family. There were no clinical complications of chronic hypercalcaemia, but five had had parathyroid surgery which was...
MUIRHEAD, N., ADAMI, S., SANDLER, L. M., FRASER, R. A., CATTO, G. R. D., EDWARD, N., ...
Twenty-three patients with end-stage renal failure on maintenance haemodialysis were treated with 1, 25-dihydroxy vitamin D3 or 24–25-dihydroxy vitamin D3 for 3–32 months (total 232 patient...
Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies.
Muirhead, N, Catto, G R, Edward, N, Adami, S, Manning, R M, O'Riordan, J L
A study was conducted evaluating the response of serum parathyroid hormone to acute hypercalcaemia and long term administration of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in patients receiving...
Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies.
Muirhead, N, Catto, G R, Edward, N, Adami, S, Manning, R M, O'Riordan, J L
A study was conducted evaluating the response of serum parathyroid hormone to acute hypercalcaemia and long term administration of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in patients receiving...
Bisphosphonate therapy of reflex sympathetic dystrophy syndrome
Adami, S, Fossaluzza, V, Gatti, D, Fracassi, E, Braga, V
OBJECTIVE—The reflex sympathetic dystrophy syndrome (RSDS) is a painful limb disorder, for which a consistently effective treatment has not yet been identified. The disease is associated with...
Background for studies on the treatment of male osteoporosis: state of the art
Kaufman, J, Johnell, O, Abadie, E, Adami, S, Audran, M, Avouac, B, ...
Male osteoporosis represents an important, although long underestimated, public health problem. Both in men and in women aging is accompanied by continuous bone loss and by an exponential increase in...
Tannenbaum, H, Berenbaum, F, Reginster, J, Zacher, J, Robinson, J, Poor, G, ...
Objectives: To compare the efficacy and safety of lumiracoxib with placebo and celecoxib for osteoarthritis OA in a 13 week, multicentre, randomised, double blind study.
Cytochemical bioassay of parathyroid hormone in maternal and cord blood.
Allgrove, J, Adami, S, Manning, R M, O'Riordan, J L
Parathyroid hormone and calcium were measured in plasma taken from pregnant women at term and from the umbilical veins of their infants at birth. Three assays were used to measure parathyroid...